XML 38 R28.htm IDEA: XBRL DOCUMENT v3.25.3

Collaborative Arrangements and Licensing Agreements (Tables)

9 Months Ended

Sep. 30, 2025

AstraZeneca [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Agreement

During the three and nine months ended September 30, 2025 and 2024, we earned the following revenue from our relationship with AstraZeneca (in thousands, except percentage amounts):

	Three Months Ended								Nine Months Ended
	September 30,								September 30,
		2025				2024				2025				2024
Revenue from our relationship with AstraZeneca	$	27,128			$	19,461			$	101,705			$	47,106
Percentage of total revenue		17	%			15	%			14	%			10	%

Ono [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Agreement

During the three and nine months ended September 30, 2025 and 2024, we earned the following revenue from our relationship with Ono (in thousands, except percentage amounts):

		Three Months Ended				Nine Months Ended
		September 30, 2025				September 30, 2025
Revenue from our relationship with Ono	$	2,979			$	282,979
Percentage of total revenue		2	%			38	%

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-20

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=ions_AstraZenecaCollaborationsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=ions_OnoCollaborationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: